Bone loss in young women with karyotypically normal spontaneous premature ovarian failure

被引:105
作者
Anasti, JN
Kalantaridou, SN
Kimzey, LM
Defensor, RA
Nelson, LM
机构
[1] NICHHD, Sect Womens Hlth, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Dept Nursing, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0029-7844(97)00583-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the effects of karotypically normal spontaneous premature ovarian failure on femoral neck bone mineral density. Methods: Eighty-nine women with karyotypically normal spontaneous premature ovarian failure who desired fertility were evaluated at a tertiary care academic center and underwent hip and spinal bone density measurements by conventional dual-photon absorptiometry. Seventy-seven of the women (87%) had sought medical advice previously and had taken a variety of estrogen and progestin replacement regimens at least intermittently. The median (range) age was 32 (20-39) years, and the median (range) time since diagnosis was 1.5 (0.5-11) years. Findings were compared with a reference group of 218 regularly menstruating women of similar age. Results: Sixty of the 89 women with premature ovarian failure (67%, 95% confidence interval 57, 77) had a femoral neck bone mineral density more than 1 standard deviation (SD) below the mean of the reference group (P < .001, chi(2) with Yates correction). Even in women in whom the bone mineral density measurement was made within just 1.5 years of the diagnosis, nearly one-half (47%) had a femoral neck bone mineral density more than 1 SD below the mean of the reference group (P < .01). Conclusion: Two-thirds of young women with karyotypically normal spontaneous premature ovarian failure have a femoral neck bone mineral density more than 1 SD below the mean of a reference group. These young women need early education regarding strategies to maintain their bone mass and ongoing medical evaluation to maintain compliance with these strategies.
引用
收藏
页码:12 / 15
页数:4
相关论文
共 20 条
[1]  
[Anonymous], 1984, J R STAT SOC C-APPL
[2]   RISK FOR DEVELOPING OSTEOPOROSIS IN UNTREATED PREMATURE MENOPAUSE [J].
BAGUR, AC ;
MAUTALEN, CA .
CALCIFIED TISSUE INTERNATIONAL, 1992, 51 (01) :4-7
[3]  
BERMUDEZ JA, 1993, FERTIL STERIL, V60, P668
[4]   Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial [J].
Bush, TL ;
Wells, HB ;
James, MK ;
BarrettConnor, E ;
Marcus, R ;
Greendale, G ;
Hunsberger, S ;
McGowan, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17) :1389-1396
[5]   Characterization of idiopathic premature ovarian failure [J].
Conway, GS ;
Kaltsas, G ;
Patel, A ;
Davies, MC ;
Jacobs, HS .
FERTILITY AND STERILITY, 1996, 65 (02) :337-341
[6]  
COULAM CB, 1986, OBSTET GYNECOL, V67, P604
[7]   BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES [J].
CUMMINGS, SR ;
BLACK, DM ;
NEVITT, MC ;
BROWNER, W ;
CAULEY, J ;
ENSRUD, K ;
GENANT, HK ;
PALERMO, L ;
SCOTT, J ;
VOGT, TM .
LANCET, 1993, 341 (8837) :72-75
[8]   Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure [J].
Kim, TJ ;
Anasti, JN ;
Flack, MR ;
Kimzey, LM ;
Defensor, RA ;
Nelson, LM .
OBSTETRICS AND GYNECOLOGY, 1997, 89 (05) :777-779
[9]  
LINDSAY R, 1984, OBSTET GYNECOL, V63, P759
[10]  
MAZESS RB, 1987, BONE MINER, V2, P211